Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 116-26-7 Chemical Structure| 116-26-7

Structure of Safranal
CAS No.: 116-26-7

Chemical Structure| 116-26-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Safranal is the main active component of saffron, exhibiting neuroprotective and anti-inflammatory effects, particularly showing potential therapeutic value in research on neurodegenerative diseases such as Parkinson's disease.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Safranal

CAS No. :116-26-7
Formula : C10H14O
M.W : 150.22
SMILES Code : O=CC1=C(C)C=CCC1(C)C
MDL No. :MFCD00209531
InChI Key :SGAWOGXMMPSZPB-UHFFFAOYSA-N
Pubchem ID :61041

Safety of Safranal

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H225-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338
Class:3
UN#:1993
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat neural stem cells (NSC) 1, 20, or 100 ng/mL 1 week SAF at 20 and 100 ng/mL significantly increased TH and DAT positive rates and promoted dopamine release. PMC6201804
HepG2 cells 1, 0.3, 0.1, 0.03, 0.01 mM 24 hours To evaluate the effect of Safranal on HepG2 cell viability. Results showed that Safranal significantly reduced HepG2 cell viability in a dose-dependent manner, with almost 70% reduction at 1 mM concentration. PMC8845597
Bone marrow-derived mast cells (BMMCs) 10 µM or 100 µM 24 hours To investigate the inhibitory effect of Safranal on degranulation and inflammatory mediator production in BMMCs. Results showed that Safranal significantly reduced the release of β-hexosaminidase and inhibited the production of IL-6, TNF-α, and LTC4. PMC8173045
Escherichia coli αR283D mutant 12 mM 60 minutes Safranal partially inhibited αR283D mutant ATP synthase PMC5884629
Escherichia coli wild-type 8 mM 60 minutes Safranal fully inhibited wild-type F1Fo ATP synthase PMC5884629
Bone marrow-derived macrophages (BMDMs) 10 or 50 µM 24 hours To evaluate the cytotoxicity of Safranal in BMDMs and inhibit the production of NO, iNOS, and COX-2. PMC6838343
RAW264.7 cells 10 or 50 µM 24 hours To evaluate the cytotoxicity of Safranal in RAW264.7 cells and inhibit the production of NO, iNOS, and COX-2. PMC6838343
HepG2 cells 30–100 μM 24 hours To assess the effects of safranal on the survival of HepG2 cells. Results showed that safranal inhibited colony formation in a dose-dependent manner, being most effective at 100 µM dose. PMC6240095
HepG2 cells 50–900 μM 24, 48, 72 hours To assess the cytotoxic effects of safranal on HepG2 cells. Results showed that safranal inhibited cellular viability in a dose- and time-dependent manner (IC50 500 μM). PMC6240095
HepG2 cells 1, 0.7, 0.5 mM 48 hours To evaluate the effect of Safranal on caspase-3 and -7 activities in HepG2 cells. Results showed that Safranal significantly increased caspase-3 and -7 activities at 1 mM concentration. PMC8845597
Human retinal microvascular endothelial cells (HRMECs) 80 μg/mL 5 days Safranal protected HRMECs from high glucose-induced cell proliferation inhibition, reduced apoptosis, and inhibited cell migration and tube formation. PMC9708741
HepG2 cells 500 μM 6–48 hours To investigate how safranal affects cell cycle progression. Results showed that safranal caused G2/M phase arrest at 6 and 12 h post treatment, S-phase arrest at 24 h, and a significant (p < 0.001) increase in sub-G1 population post 24 and 48 h of treatment, indicating apoptosis induction. PMC6240095
Rat aortic rings 0.01–1 μM To investigate the vasodilatory effect of Safranal on phenylephrine-precontracted aortic rings, results showed that Safranal caused vasodilation in both endothelium-intact and endothelium-denuded aortic rings. PMC9268204

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Wistar rats DEN/2-AAF-induced liver cancer model Oral 0.025 ml/kg and 0.05 ml/kg Daily administration for 12 weeks To evaluate the preventive effect of Safranal on DEN/2-AAF-induced liver cancer model. Results showed that Safranal significantly inhibited the formation of pre-neoplastic lesions, reduced the number and area of GST-p-positive foci, inhibited cell proliferation (Ki-67), induced apoptosis (TUNEL and M30 CytoDeath), and exhibited anti-inflammatory properties (inhibition of NF-kB, COX2, iNOS, TNF-alpha, and its receptor). PMC8845597
BALB/c mice OVA-induced asthma model and passive systemic anaphylaxis (PSA) model Oral 200 mg/kg or 500 mg/kg Once daily for 7 days To evaluate the anti-allergic effects of Safranal in OVA-induced asthma model and PSA model. Results showed that Safranal significantly reduced serum IgE levels, decreased mast cell infiltration in lung tissue, and balanced Th1/Th2 cytokine levels. In the PSA model, Safranal reduced the levels of histamine and LTC4 in serum. PMC8173045
BALB/c mice DSS-induced colitis model Oral 200 mg/kg or 500 mg/kg Once daily for 7 days To evaluate the clinical and histological effects of Safranal in DSS-induced colitis mice. PMC6838343
C57BL/6J mice Pentobarbital-treated mice model Intragastrically 90, 180, or 360 mg/kg Single administration, observed for 3 hours Safranal increased the duration of non-rapid eye movement (NREM) sleep, shortened NREM sleep latency, and enhanced the delta power activity of NREM sleep. Immunohistochemical evaluation revealed that safranal increased c-Fos expression in the ventrolateral preoptic nucleus (VLPO), one of the putative sleep centers, and decreased it in the arousal histaminergic tuberomammillary nuclei (TMN). PMC6493539
Sprague-Dawley rats 6-OHDA-induced Parkinson's disease model Intrastriatal injection 2 μL (100 ng/mL) 2 and 4 weeks after transplantation Transplantation of SAF-treated NSC significantly reduced rotation numbers, increased survival rates, and promoted the differentiation and survival of dopaminergic neurons. PMC6201804

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.66mL

1.33mL

0.67mL

33.28mL

6.66mL

3.33mL

66.57mL

13.31mL

6.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories